Scatr

Scatr is a private healthcare technology company developing portable drug-detection instruments and related software for point-of-care and frontline substance analysis. Its lead commercialized product appears to be the Scatr Series One, a portable device used to analyze real drug samples in real time and surface actionable results through the cloud-based Scatr Dashboard. The company positions its technology for public health, harm reduction, forensics, security, and pharmaceutical use cases, with a stated mission to reduce overdose rates through accessible testing. Through its affiliated Scatr Medical effort, the company is also developing Duversa, an overdose reversal formulation intended for fentanyl-xylazine and related overdoses, which appears to remain at a preclinical stage. Overall, Scatr is best characterized as an active private health-tech and medical-device company with an emerging drug-development program tied to overdose intervention.